🔎 Trials Near Me

Beranda › Makroglobulinemia Waldenstrom › Washington

Uji klinis Makroglobulinemia Waldenstrom di Washington

7 studi untuk Makroglobulinemia Waldenstrom mencari peserta di lokasi di Washington.

Kota di Washington

Teks studi resmi (Bahasa Inggris)

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Fred Hutchinson Cancer Research Center, Seattle
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

  • Swedish Cancer Institute-Edmonds, Edmonds
  • Swedish Cancer Institute-Issaquah, Issaquah
  • Swedish Medical Center-First Hill, Seattle
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04840602

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

  • Medical Oncology Associates (Summit Cancer Centers) ( Site 2710), Spokane
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04728893

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Swedish Cancer Institute (SCI), Seattle
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328

A Study of ARC-02 in B-cell NHL

  • Summit Cancer Centers - North Spokane, Spokane
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07691606

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Fred Hutchinson Cancer Center, Seattle
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT05544019

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • Swedish Cancer Institute, Seattle
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2025 · NCT05780034

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.